Project Grant HT94252410342
Award Date
9/30/24
Completion Date
8/31/27
Dollars Obligated
$409K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33620, USA
Similar Awards
This $816,676 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a study by the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to conduct a multiomic evaluation of ovarian cancer responses to heated intraperitoneal chemotherapy (HIPEC). The 3-year study, with a period of performance from September 30, 2024 to August 31, 2027, aims to advance understanding of how HIPEC...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $276,721 to Florida State University to improve targeted ovarian cancer therapy using the novel Notch pathway inhibitor auranofin. The award period runs from July 1, 2024 to June 30, 2027. The funded research aims to advance the scientific understanding and development of innovative treatments for ovarian cancer, a critical medical challenge for military...
The University of Pittsburgh received a $454,142.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "FERROPTOSIS AS A METABOLIC VULNERABILITY OF CYCLIN E-HIGH OVARIAN CANCER". This 2-year research project, with a performance period from May 2024 to May 2026, aims to investigate metabolic vulnerabilities in a specific type of ovarian cancer. The University of Pittsburgh is the primary...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
The federal Project Grant award of $457,185.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a research project led by Clemson University to characterize fallopian tube-derived extracellular vesicles for the discovery of ovarian cancer biomarkers. The 2-year project, running from July 1, 2024 to June 30, 2026, will leverage Clemson University's expertise in areas like cancer research, biomedical engineering, and...
This Project Grant from the Defense Health Agency provides $494,811 to the University of Cambridge under the Military Medical Research and Development program (CFDA 12.420) from April 1, 2023 to March 31, 2026. The grant funds research to elucidate and target clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
This $466,500 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by The Washington University to leverage the ovarian tumor microenvironment for early detection strategies. The award, effective August 1, 2025 through July 31, 2027, will fund innovative biomedical research focused on transforming healthcare for military service members and the public. The research aims to develop...
The University of Oklahoma Health Sciences Center was awarded an $864,781 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from April 1, 2023 to March 31, 2026 targeting DCLK1-driven chemoresistance in ovarian cancer. The goal aligns with the Military Medical Research and Development program's focus on innovative medical solutions for Service Members and the public through...